|
P. Lissoni1,*, F. Rovelli1, G. Messina2,
F. Brivio3, B. Boniardi1, G. Porro1,
L.Vigore4, G. Di Fede1, P. Marchiori1,
G. Brera5
Summary
Background: The recent advances in understanding the
immunobiological interactions responsible for cancer progression
have allowed us to define the mechanisms of action of some
plants, whose antitumor properties were already known by the
popular Medicine, in particular Aloe and Myrrha, whose mixture
was already therapeutically utilized more than 2000 years ago by
the Essence medicine. Moreover, some endogenous natural
substances, namely the main hormone produced by the pineal gland
melatonin (MLT) may also play anticancer activity. On this basis,
a study was performed with a biological regimen consisting of
MLT, Aloe and Myrrha in untreatable metastatic cancer patients
with life expectancy lower than 1 year. Methods: The study
included 35 patients. MLT was given orally at 20 mg/day in the
evening and a mixed Aloe and Myrrha tincture was administered at
a dose of 5 ml/thrice daily. Results: The clinical response
consisted of complete response (CR) in 1, partial response (PR)
in 2, stable disease (SD) in 19 patients, whereas the remaining
13 patients had a progressive disease (PD). Thus, a disease
control (CR + PR + SD) was achieved in 22/35 (63%)patients.
Moreover, a survival longer than 1 year was achieved in 17/35
(49%) patients. Finally, DC was associated with an evident
improvement in the immune status, namely consisting of a
decrease in the number of T regulatory lymphocytes, which are
the main cells responsible for the suppression of the anticancer
immunity. Conclusion: This preliminary study shows that a
biological anticancer regimen consisting of the pineal hormone
MLT in association with Aloe and Myrrha mixture, already known
at the times of the Essence medical tradition, may induce a
control of the neoplastic disease by stimulating the anticancer
immunity, in a relevant percentage metastatic cancer patients,
who did not respond to the conventional anticancer treatments
and for whom no other standard therapy was available.
References
Davis RH, Parker WL, Sampson RT, Murdoch DP. Isolation of a
stimulatory system in an Aloe extract. J Am Pediatr Med Assoc
1991; 81:473-8.
Capasso F, Borrelli F, Capasso R, Di Carlo G, Izzo AA, Pinto
L et al. Aloe and its therapeutic use. Phytother Res 1998;
12:124-7.
Vogler BK. Aloe Vera: a systematic review of its clinical
effectiveness. B J Gen Pract 1999; 49:823-8.
Claeson P, Zygmunt P, Hogestatt ED. Calcium antagonistic
properties of the sesquiterpene T- cadinol. Pharmacol Toxicol
1991; 69:173-7.
Qureshi S, Al-Harbi MM, Ahmed M, Raza M, Giangreco AB, Shah
AH. Evaluation of the genotixic, cytotoxic and antitumor
properties of Commiphora molmol using normal and Erlich ascites
carcinoma cell-bearing Swiss albino mice. Cancer Chemother
Pharmacol 1993; 33130-8.
Blazquez C, Casanova ML, Planas A, Del Pulgar TG, Villanueva
C, Fernandez-Acenero MJ et al. Inhibition of tumor angiogenesis
by cannabinoids. FASEB J 2003; 17:529-31.
Grotenhermen F. Pharmacology of cannabinoids. Neuroendocrinol
Lett 2004; 25:14-23.
Aggarwall BB, Kumar A, Bharti AC. Anticancer potential of
curcumin. Preclinical and clinical studies. Anticancer Res 2003;
23:363-98.
Lodha R, Bagga A. Tradictional Indian system of Medicine. Ann
Acad Med Singapore 2000; 29:37-41.
John's Gospel 19,38-40.
Iguchi H, Kato KI, Ibayashi H. Age-dependent reduction in
serum melatonin concentrations in healthy subjects. J Clin
Endocrinol Metab 1982; 55:27-9.
Attanasio A, Borrelli P, Gupta D. Circadian rhythms in serum
melatonin from infancy to adolescence. J Clin Endocrinol Metab
1985; 61:388-90.
Jankovic BD. Neuroimmunomodulation. Ann NY Acad Sci 1994;
741:3-38.
Brzezinski A. Melatonin in humans. N Engl J Med 1997;
336:185-95
Bartsch H, Bartsch C. Effects of melatonin on experimental
tumors under different photoperiods and times of administration.
J neural Transm 1981; 52:269-79
Regelson W, Pierpaoli W. Melatonin: a rediscovered antitumor
hormone? Cancer Invest
1987; 5:379-85
Lissoni P. Is there a role for melatonin in supportive care?
Supp Care Cancer 2002; 10:110-6.
Sze S, Ng T, Liu W. Antiproliferative effect of pineal indoles
on cultured tumor cell lines. J Pineal Res 1993; 14:27-33.
Maestroni GJM. The immunoneuroendocrine role of melatonin. J
Pineal Res 1993; 14:1-10.
Lissoni P, Brivio F, Fumagalli L, Messina G,Vigorè L,
Parolini D et al. : Neuroimmunomodulation in Medical Oncology:
application of Psychoneuroimmunology with subcutaneous low-dose
IL-2 plus the pineal hormone melatonin in patients with
untreatable metastatic solid tumors. Anticancer Res 2008;
28:1377-82.
Shevach EM. CD4+CD25+ suppressor T cells: more questions than
answers. Nat Rev Immunol 2002; 2:389-400.
Rorschach H. Psychodiagnosytics. Ed HA Huber, Bern, Stuttgart,
Toronto. Verlag, 1921.
Lissoni P, Messina G, Parolini D, Balestra A, Brivio F,
Fumagalli L et al.:A spiritual approach in the treatment of
cancer. In Vivo 2008; 22:557-82.
|
Disbiosi
Intestinale 
